newsfilter
← Latest News
GlobeNewswire·

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple programs in metabolic and